BofA analyst Tal Liani raised the firm’s price target on Cellebrite to $13 from $12 and keeps a Buy rating on the shares. Cellebrite provided long-term growth targets at its Investor Day event, including improved business momentum in 2024 and beyond, driven by healthy market demand, growth acceleration of new product initiatives, and the transition over the last few years from a best-of-breed point solution vendor for mobile extraction capabilities to an end-to-end platform, the analyst tells investors in a research note. The firm remains positive on the opportunity for durable growth ahead.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite to host investor day
- Cellebrite appoints David Gee as CMO
- Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership
- Cellebrite Files its 2023 Annual Report on Form 20-F
- Cellebrite Revolutionizes Data Collection with Ground-breaking SaaS Solution, Integral Part of Company’s Case-to-Closure Platform